Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole.
Wang, T., Duffy, J.P., Wang, J., Halas, S., Salituro, F.G., Pierce, A.C., Zuccola, H.J., Black, J.R., Hogan, J.K., Jepson, S., Shlyakter, D., Mahajan, S., Gu, Y., Hoock, T., Wood, M., Furey, B.F., Frantz, J.D., Dauffenbach, L.M., Germann, U.A., Fan, B., Namchuk, M., Bennani, Y.L., Ledeboer, M.W.(2009) J Med Chem 52: 7938-7941
- PubMed: 20014869 
- DOI: https://doi.org/10.1021/jm901383u
- Primary Citation of Related Structures:  
3JY9 - PubMed Abstract: 
The synthesis and characterization of a novel polycyclic azaindole based derivative is disclosed, and its binding to JAK2 is described. The compound is further evaluated for its ability to block the EPO/JAK2 signaling cascade in vitro and in vivo.
Organizational Affiliation: 
Vertex Pharmaceuticals Inc., Cambridge, Massachusetts 02139-4242, USA.